{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:57:58Z","timestamp":1790629078136,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-026-01998-3","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:04:34Z","timestamp":1790582674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic architecture and molecular pathogenesis of Parkinson\u2019s disease: emerging mechanisms and therapeutic targets"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5402-3140","authenticated-orcid":false,"given":"Sumeyye","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1998_CR1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/ijms27010486","volume":"27","author":"S Ahmed","year":"2026","unstructured":"Ahmed S, Pasam T, Afreen F (2026) Mitophagy-NLRP3 inflammasome crosstalk in Parkinson\u2019s disease: Pathogenic mechanisms and emerging therapeutic strategies. Int J Mol Sci 27:486. https:\/\/doi.org\/10.3390\/ijms27010486","journal-title":"Int J Mol Sci"},{"key":"1998_CR2","doi-asserted-by":"publisher","first-page":"108973","DOI":"10.1016\/j.compbiolchem.2026.108973","volume":"123","author":"P Alam","year":"2026","unstructured":"Alam P, Hasan GM, Mohammad T, Hassan MI (2026) Next-generation computational strategies for neurodegenerative biomarkers: Multi-omics integration, AI, and molecular modeling. Comput Biol Chem 123:108973. https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.108973","journal-title":"Comput Biol Chem"},{"key":"1998_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","volume":"272","author":"M Alfaidi","year":"2025","unstructured":"Alfaidi M, Barker RA, Kuan WL (2025) An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease. J Neurol 272:21. https:\/\/doi.org\/10.1007\/s00415-024-12770-x","journal-title":"J Neurol"},{"key":"1998_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ana.26949","volume":"96","author":"G Arena","year":"2024","unstructured":"Arena G, Landoulsi Z, Grossmann D, Payne T, Vitali A, Delcambre S et al (2024) Polygenic risk scores validated in patient-derived cells stratify for mitochondrial subtypes of Parkinson\u2019s disease. Ann Neurol 96:133\u2013149. https:\/\/doi.org\/10.1002\/ana.26949","journal-title":"Ann Neurol"},{"key":"1998_CR5","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.3390\/ijms26115405","volume":"26","author":"O Arias-Carri\u00f3n","year":"2025","unstructured":"Arias-Carri\u00f3n O, Guerra-Crespo M, Padilla-God\u00ednez FJ, Soto-Rojas LO, Manjarrez E (2025) \u03b1-Synuclein pathology in synucleinopathies: Mechanisms, biomarkers, and therapeutic challenges. Int J Mol Sci 26:5405. https:\/\/doi.org\/10.3390\/ijms26115405","journal-title":"Int J Mol Sci"},{"key":"1998_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov Today 21:802\u2013818. https:\/\/doi.org\/10.1016\/j.drudis.2016.01.013","journal-title":"Drug Discov Today"},{"key":"1998_CR7","doi-asserted-by":"publisher","first-page":"149204","DOI":"10.1016\/j.brainres.2024.149204","volume":"1845","author":"K Bhardwaj","year":"2024","unstructured":"Bhardwaj K, Jha A, Roy A, Kumar H (2024) The crucial role of VPS35 and SHH in Parkinson\u2019s disease: Understanding the mechanisms behind the neurodegenerative disorder. Brain Res 1845:149204. https:\/\/doi.org\/10.1016\/j.brainres.2024.149204","journal-title":"Brain Res"},{"key":"1998_CR8","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/genes16121496","volume":"16","author":"A Bougea","year":"2025","unstructured":"Bougea A (2025) Underlying mechanisms of GBA1 in Parkinson\u2019s disease and dementia with Lewy bodies: Narrative review. Genes 16:1496. https:\/\/doi.org\/10.3390\/genes16121496","journal-title":"Genes"},{"key":"1998_CR9","doi-asserted-by":"publisher","unstructured":"Chahine LM, Alcalay RN, Brown EG, Chowdhury S, Coffey CS, Foroud T et al (2026) Biologic frameworks for synucleinopathies: Contributions of the Parkinson\u2019s progression markers initiative. Annals of Neurology. https:\/\/doi.org\/10.1002\/ana.78249. Advance online publication","DOI":"10.1002\/ana.78249"},{"key":"1998_CR10","doi-asserted-by":"publisher","first-page":"205520762614320","DOI":"10.1177\/20552076261432053","volume":"12","author":"R Chauhan","year":"2026","unstructured":"Chauhan R, Sharma U, Singh D (2026) AI-powered speech analysis for early prediction of Parkinson\u2019s disease: Quantitative hypokinetic dysarthria as a biomarker for early Parkinson\u2019s detection: A machine learning approach. Digit Health 12:20552076261432053. https:\/\/doi.org\/10.1177\/20552076261432053","journal-title":"Digit Health"},{"key":"1998_CR11","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1038\/s41467-024-46538-8","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen S, Puri A, Bell B, Fritsche J, Palacios HH, Balch M et al (2024) HTRA1 disaggregates \u03b1-synuclein amyloid fibrils and converts them into non-toxic and seeding incompetent species. Nat Commun 15:2436. https:\/\/doi.org\/10.1038\/s41467-024-46538-8","journal-title":"Nat Commun"},{"key":"1998_CR12","doi-asserted-by":"publisher","first-page":"2401641","DOI":"10.1002\/advs.202401641","volume":"11","author":"JP Dobert","year":"2024","unstructured":"Dobert JP, Bub S, M\u00e4chtel R, Januliene D, Steger L, Regensburger M et al (2024) Activation and purification of \u03b2-glucocerebrosidase by exploiting its transporter LIMP-2 \u2013 implications for novel treatment strategies in Gaucher\u2019s and Parkinson\u2019s disease. Adv Sci 11:2401641. https:\/\/doi.org\/10.1002\/advs.202401641","journal-title":"Adv Sci"},{"key":"1998_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1042\/BCJ20253099","volume":"482","author":"N Dzamko","year":"2025","unstructured":"Dzamko N (2025) Leucine-rich repeat kinase 2 biomarkers for Parkinson\u2019s disease. Biochem J 482:709\u2013720. https:\/\/doi.org\/10.1042\/BCJ20253099","journal-title":"Biochem J"},{"key":"1998_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40263-026-01275-y","volume":"40","author":"N Dzamko","year":"2026","unstructured":"Dzamko N (2026) Pathological protein targets in Parkinson\u2019s disease: Progress towards the development of disease-modifying therapies. CNS Drugs 40:509\u2013522. https:\/\/doi.org\/10.1007\/s40263-026-01275-y","journal-title":"CNS Drugs"},{"key":"1998_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00702-022-02505-5","volume":"129","author":"PB Foley","year":"2022","unstructured":"Foley PB, Hare DJ, Double KL (2022) A brief history of brain iron accumulation in Parkinson disease and related disorders. J Neural Transm 129:505\u2013520. https:\/\/doi.org\/10.1007\/s00702-022-02505-5","journal-title":"J Neural Transm"},{"key":"1998_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1877718X251392799","volume":"16","author":"KB Fraser","year":"2026","unstructured":"Fraser KB, Mirelman A, Mabrouk OS, Omer N, Concha-Marambio L, Gurevich T et al (2026) Analysis of \u03b1-synuclein seed amplification assay in carriers of GBA1 and LRRK2 pathogenic variants. J Parkinsons Dis 16:205\u2013216. https:\/\/doi.org\/10.1177\/1877718X251392799","journal-title":"J Parkinsons Dis"},{"key":"1998_CR17","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1177\/1877718X251361507","volume":"15","author":"HL Frequin","year":"2025","unstructured":"Frequin HL, Ferwerda B, Verschuur CV, Suwijn SR, Dijk JM, Bie RM (2025) Faster disease progression in Parkinson\u2019s disease with glucocerebrosidase genotype: But not apparent immediate from diagnosis. J Parkinson\u2019s Disease 15:1208\u20131217. https:\/\/doi.org\/10.1177\/1877718X251361507","journal-title":"J Parkinson\u2019s Disease"},{"key":"1998_CR18","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/ijms27041800","volume":"27","author":"T Fujii","year":"2026","unstructured":"Fujii T, Shimizu T, Sakai H (2026) Pathophysiological roles of two intracellular P-type ATPases: The cancer-associated Na+,K+-ATPase \u03b13 isoform and the Parkinson\u2019s disease-related ATP13A2. Int J Mol Sci 27:1800. https:\/\/doi.org\/10.3390\/ijms27041800","journal-title":"Int J Mol Sci"},{"key":"1998_CR19","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/s41401-025-01499-6","volume":"46","author":"XD Gao","year":"2025","unstructured":"Gao XD, Ding JE, Xie JX, Xu HM (2025) Epigenetic regulation of iron metabolism and ferroptosis in Parkinson\u2019s disease: Identifying novel epigenetic targets. Acta Pharmacol Sin 46:2075\u20132092. https:\/\/doi.org\/10.1038\/s41401-025-01499-6","journal-title":"Acta Pharmacol Sin"},{"key":"1998_CR21","doi-asserted-by":"publisher","first-page":"29507","DOI":"10.1038\/s41598-025-14735-0","volume":"15","author":"V Gorgogietas","year":"2025","unstructured":"Gorgogietas V, Weiss A, Cousin L, Hoffmann D, Schmitt K, Ogier A et al (2025) Morphological profiling reveals neuroprotection via mitochondrial uncoupling in human dopaminergic neurons. Sci Rep 15:29507. https:\/\/doi.org\/10.1038\/s41598-025-14735-0","journal-title":"Sci Rep"},{"key":"1998_CR22","doi-asserted-by":"publisher","first-page":"e70540","DOI":"10.1002\/mco2.70540","volume":"6","author":"XY Guo","year":"2025","unstructured":"Guo XY, Song DY, Wu MY, Zhang JQ, Li JY, Yuan L (2025) Parkinson\u2019s disease: the epidemiology, risk factors, molecular pathogenesis, prevention, and therapy. MedComm 6:e70540. https:\/\/doi.org\/10.1002\/mco2.70540","journal-title":"MedComm"},{"key":"1998_CR23","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1877718X251339201","volume":"15","author":"AM Hanff","year":"2025","unstructured":"Hanff AM, McCrum C, Rauschenberger A, Aguayo GA, Pauly C, J\u00f3nsd\u00f3ttir SR et al (2025) Sex-specific progression of Parkinson\u2019s disease: A longitudinal mixed-models analysis. J Parkinson\u2019s Disease 15:805\u2013818. https:\/\/doi.org\/10.1177\/1877718X251339201","journal-title":"J Parkinson\u2019s Disease"},{"key":"1998_CR24","doi-asserted-by":"publisher","first-page":"1771789","DOI":"10.3389\/fnagi.2026.1771789","volume":"18","author":"AM Hanff","year":"2026","unstructured":"Hanff AM, McCrum C, Rauschenberger A, Pachchek S, Aguayo GA, Pauly C et al (2026) Progression of GBA1 severe and risk variants: A longitudinal mixed model analysis. Front Aging Neurosci 18:1771789. https:\/\/doi.org\/10.3389\/fnagi.2026.1771789","journal-title":"Front Aging Neurosci"},{"key":"1998_CR25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/mds.70168","volume":"41","author":"MJ Henderson","year":"2026","unstructured":"Henderson MJ, Chen TC, Glasstetter LM, Chen Y, Marugan JJ, Sidransky E (2026) The race to salvage glucocerebrosidase: Understanding small-molecule therapies for GBA1-associated parkinsonism. Mov Disord 41:596\u2013602. https:\/\/doi.org\/10.1002\/mds.70168","journal-title":"Mov Disord"},{"key":"1998_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10072-026-08963-z","volume":"47","author":"H Hu","year":"2026","unstructured":"Hu H, Wang M, Yang Y, Wei Z (2026) Neuroinflammation plays a crucial role in the pathogenesis of Parkinson\u2019s disease: A systematic review and meta-analysis of clinical and biomarker evidence. Neurol Sci 47:399. https:\/\/doi.org\/10.1007\/s10072-026-08963-z","journal-title":"Neurol Sci"},{"key":"1998_CR27","doi-asserted-by":"publisher","first-page":"156652","DOI":"10.1016\/j.phymed.2025.156652","volume":"141","author":"YB Huang","year":"2025","unstructured":"Huang YB, Tian LL, Zhu ZW, Zhou KG, Lai X, Peng YZ et al (2025) Apigenin enhances Nrf2-induced chaperone-mediated autophagy and mitigates \u03b1-synuclein pathology: Implications for Parkinson\u2019s disease therapy. Phytomedicine 141:156652. https:\/\/doi.org\/10.1016\/j.phymed.2025.156652","journal-title":"Phytomedicine"},{"key":"1998_CR28","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mdc3.70011","volume":"12","author":"M Kals","year":"2025","unstructured":"Kals M, Reigo A, Teder-Laving M, Vaht M, Nikopensius T, Metspalu A, Toomsoo T (2025) Polygenic risk score combined with transcranial sonography refines Parkinson\u2019s disease risk prediction. Mov Disord Clin Pract 12:928\u2013937. https:\/\/doi.org\/10.1002\/mdc3.70011","journal-title":"Mov Disord Clin Pract"},{"key":"1998_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11011-025-01552-7","volume":"40","author":"M Kaur","year":"2025","unstructured":"Kaur M, Aran KR (2025) Unraveling the role of Nrf2 in dopaminergic neurons: A review of oxidative stress and mitochondrial dysfunction in Parkinson\u2019s disease. Metab Brain Dis 40:123. https:\/\/doi.org\/10.1007\/s11011-025-01552-7","journal-title":"Metab Brain Dis"},{"key":"1998_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/1877718X251397277","volume":"16","author":"S Kayhanian","year":"2026","unstructured":"Kayhanian S, Barker RA (2026) Clinical trial highlights: Dopamine cell-replacement therapies. J Parkinson\u2019s Disease 16:8\u201315. https:\/\/doi.org\/10.1177\/1877718X251397277","journal-title":"J Parkinson\u2019s Disease"},{"key":"1998_CR31","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.3390\/ijms26136416","volume":"26","author":"MS Khan","year":"2025","unstructured":"Khan MS, Nasiripour S, Bopassa JC (2025) Parkinson disease signaling pathways, molecular mechanisms, and potential therapeutic strategies: A comprehensive review. Int J Mol Sci 26:6416. https:\/\/doi.org\/10.3390\/ijms26136416","journal-title":"Int J Mol Sci"},{"key":"1998_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41531-025-01171-0","volume":"11","author":"R Kinet","year":"2025","unstructured":"Kinet R, Sikora J, Arotcarena ML, Decourt M, Balado E, Doudnikoff E et al (2025) Phenotypic characterization of an Atp13a2 knockout rat model of Parkinson\u2019s disease. NPJ Parkinson\u2019s Disease 11:321. https:\/\/doi.org\/10.1038\/s41531-025-01171-0","journal-title":"NPJ Parkinson\u2019s Disease"},{"key":"1998_CR33","doi-asserted-by":"publisher","first-page":"e96090","DOI":"10.7759\/cureus.96090","volume":"17","author":"R Kniazev","year":"2025","unstructured":"Kniazev R (2025) Immunotherapy in early Parkinson\u2019s disease: A biomarker-driven trial framework for secondary prevention. Cureus 17:e96090. https:\/\/doi.org\/10.7759\/cureus.96090","journal-title":"Cureus"},{"key":"1998_CR34","doi-asserted-by":"publisher","first-page":"e56399","DOI":"10.15252\/embr.202256399","volume":"24","author":"F Kraus","year":"2023","unstructured":"Kraus F, Goodall EA, Smith IR, Jiang Y, Paoli JC, Adolf F et al (2023) PARK15\/FBXO7 is dispensable for PINK1\/Parkin mitophagy in iNeurons and HeLa cell systems. EMBO Rep 24:e56399. https:\/\/doi.org\/10.15252\/embr.202256399","journal-title":"EMBO Rep"},{"key":"1998_CR35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s13346-025-01944-3","volume":"16","author":"M Kwatra","year":"2026","unstructured":"Kwatra M, Kwak G, Li H, Suk JS, Ko HS (2026) Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson\u2019s disease. Drug Delivery Translational Res 16:894\u2013910. https:\/\/doi.org\/10.1007\/s13346-025-01944-3","journal-title":"Drug Delivery Translational Res"},{"key":"1998_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41531-025-00933-0","volume":"11","author":"LM Lange","year":"2025","unstructured":"Lange LM, Cerquera-Cleves C, Schipper M, Panagiotaropoulou G, Braun A, Kraft J et al (2025) Prioritizing Parkinson\u2019s disease risk genes in genome-wide association loci. NPJ Parkinsons Dis 11:77. https:\/\/doi.org\/10.1038\/s41531-025-00933-0","journal-title":"NPJ Parkinsons Dis"},{"key":"1998_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1474-4422(26)00198-5","volume":"25","author":"LM Lange","year":"2026","unstructured":"Lange LM, Fang ZH, Makarious MB, Kuznetsov N, Atterling Brolin K, Ballard S et al (2026) Parkinson\u2019s disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications. Lancet Neurol 25:741\u2013754. https:\/\/doi.org\/10.1016\/S1474-4422(26)00198-5","journal-title":"Lancet Neurol"},{"key":"1998_CR39","doi-asserted-by":"publisher","first-page":"e2513317123","DOI":"10.1073\/pnas.2513317123","volume":"123","author":"CM Lim","year":"2026","unstructured":"Lim CM, Vendruscolo M (2026) The \u03b1-synuclein proteostasis network and its translational applications in Parkinson\u2019s disease. Proc Natl Acad Sci USA 123:e2513317123. https:\/\/doi.org\/10.1073\/pnas.2513317123","journal-title":"Proc Natl Acad Sci USA"},{"key":"1998_CR40","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1474-4422(24)00378-8","volume":"23","author":"SY Lim","year":"2024","unstructured":"Lim SY, Tan AH, Ahmad-Annuar A, Okubadejo NU, Lohmann K, Morris HR et al (2024) Uncovering the genetic basis of Parkinson\u2019s disease globally: from discoveries to the clinic. Lancet Neurol 23:1267\u20131280. https:\/\/doi.org\/10.1016\/S1474-4422(24)00378-8","journal-title":"Lancet Neurol"},{"key":"1998_CR38","doi-asserted-by":"publisher","first-page":"e0329980","DOI":"10.1371\/journal.pone.0329980","volume":"21","author":"W Liu","year":"2026","unstructured":"Liu W, Xu L, Wang X, Wang J (2026) Integrative multi-omics and network-based machine learning for early diagnosis of Parkinson\u2019s disease. PLoS ONE 21:e0329980. https:\/\/doi.org\/10.1371\/journal.pone.0329980","journal-title":"PLoS ONE"},{"key":"1998_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/15548627.2025.2581217","volume":"22","author":"J Lu","year":"2026","unstructured":"Lu J, Di Florio DN, Boya P, Maday S, Springer W, Chu CT (2026) Autophagy and mitophagy at the synapse and beyond: Implications for learning, memory and neurological disorders. Autophagy 22:10\u201352. https:\/\/doi.org\/10.1080\/15548627.2025.2581217","journal-title":"Autophagy"},{"key":"1998_CR42","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41591-026-04262-4","volume":"32","author":"OS Mabrouk","year":"2026","unstructured":"Mabrouk OS, Tichler B, Arnold HM, Thoma EC, Alexanian SM, Chen J et al (2026) LRRK2-targeting antisense oligonucleotide in Parkinson\u2019s disease: A phase 1 randomized controlled trial. Nat Med 32:1421\u20131431. https:\/\/doi.org\/10.1038\/s41591-026-04262-4","journal-title":"Nat Med"},{"key":"1998_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0045-1802962","volume":"83","author":"DP Maia","year":"2025","unstructured":"Maia DP, Cury RG, Brand\u00e3o PRP, Cardoso FEC, Bertholo AP, Felicio AC et al (2025) Guidelines for Parkinson\u2019s disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology \u2013 non-motor symptoms. Arq Neuropsiquiatr 83:1\u201315. https:\/\/doi.org\/10.1055\/s-0045-1802962","journal-title":"Arq Neuropsiquiatr"},{"key":"1998_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41531-024-00677-3","volume":"10","author":"PJ Menon","year":"2024","unstructured":"Menon PJ, Sambin S, Criniere-Boizet B, Courtin T, Tesson C, Casse F et al (2024) Genotype-phenotype correlation in PRKN-associated Parkinson\u2019s disease. NPJ Parkinson\u2019s Disease 10:72. https:\/\/doi.org\/10.1038\/s41531-024-00677-3","journal-title":"NPJ Parkinson\u2019s Disease"},{"key":"1998_CR45","doi-asserted-by":"publisher","first-page":"125806","DOI":"10.1016\/j.jns.2026.125806","volume":"482","author":"M Messak","year":"2026","unstructured":"Messak M, Abdelmageed A, Khattab YA, Altalab G, Mandour Y, Shaker O (2026) \u03b1-Synuclein monoclonal antibodies in Parkinson\u2019s disease: A failed promise or unmet potential? J Neurol Sci 482:125806. https:\/\/doi.org\/10.1016\/j.jns.2026.125806","journal-title":"J Neurol Sci"},{"key":"1998_CR46","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s11064-023-03904-0","volume":"48","author":"S Moradi Vastegani","year":"2023","unstructured":"Moradi Vastegani S, Nasrolahi A, Ghaderi S, Belali R, Rashno M, Farzaneh M et al (2023) Mitochondrial dysfunction and Parkinson\u2019s disease: Pathogenesis and therapeutic strategies. Neurochem Res 48:2285\u20132308. https:\/\/doi.org\/10.1007\/s11064-023-03904-0","journal-title":"Neurochem Res"},{"key":"1998_CR47","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s40120-025-00800-3","volume":"14","author":"T M\u00fcller","year":"2025","unstructured":"M\u00fcller T (2025) Update on the present and future pharmacologic treatment of Parkinson\u2019s disease. Neurol Therapy 14:1769\u20131781. https:\/\/doi.org\/10.1007\/s40120-025-00800-3","journal-title":"Neurol Therapy"},{"key":"1998_CR48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13041-025-01235-5","volume":"18","author":"S Noda","year":"2025","unstructured":"Noda S, Hattori N (2025) Unraveling the mystery: How autophagy deficiency in dopaminergic neurons drives human Parkinson\u2019s disease. Mol Brain 18:66. https:\/\/doi.org\/10.1186\/s13041-025-01235-5","journal-title":"Mol Brain"},{"key":"1998_CR49","doi-asserted-by":"publisher","first-page":"1924943","DOI":"10.3389\/fneur.2026.1924943","volume":"17","author":"S Noda","year":"2026","unstructured":"Noda S, Hattori N (2026) \u03b1-Synuclein burden amplification in Parkinson\u2019s disease: a unified genetic, molecular, and cellular framework. Front Neurol 17:1924943. https:\/\/doi.org\/10.3389\/fneur.2026.1924943","journal-title":"Front Neurol"},{"key":"1998_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41531-023-00484-2","volume":"9","author":"J Obergasteiger","year":"2023","unstructured":"Obergasteiger J, Castonguay AM, Pizzi S, Magnabosco S, Frapporti G, Lobbestael E et al (2023) The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology. NPJ Parkinsons Dis 9:44. https:\/\/doi.org\/10.1038\/s41531-023-00484-2","journal-title":"NPJ Parkinsons Dis"},{"key":"1998_CR51","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X261431949","author":"LM Oliveira","year":"2026","unstructured":"Oliveira LM, Frasier M, Hutten SJ (2026) Collaborative action for biomarker breakthroughs: Validating \u03b1-synuclein seed amplification assays in Parkinson\u2019s disease. J Parkinson\u2019s Disease Adv online publication. https:\/\/doi.org\/10.1177\/1877718X261431949","journal-title":"J Parkinson\u2019s Disease Adv online publication"},{"key":"1998_CR52","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1474-4422(25)00157-7","volume":"24","author":"CD Orr\u00fa","year":"2025","unstructured":"Orr\u00fa CD, Vaughan DP, Vijiaratnam N, Real R, Martinez-Carrasco A, Fumi R et al (2025) Diagnostic and prognostic value of \u03b1-synuclein seed amplification assay kinetic measures in Parkinson\u2019s disease: A longitudinal cohort study. Lancet Neurol 24:580\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(25)00157-7","journal-title":"Lancet Neurol"},{"key":"1998_CR53","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T et al (2024a) Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial. Nat Med 30:3669\u20133675. https:\/\/doi.org\/10.1038\/s41591-024-03270-6","journal-title":"Nat Med"},{"key":"1998_CR54","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB et al (2024b) Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med 30:1096\u20131103. https:\/\/doi.org\/10.1038\/s41591-024-02886-y","journal-title":"Nat Med"},{"key":"1998_CR55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.neuroscience.2026.02.035","volume":"600","author":"SP Panda","year":"2026","unstructured":"Panda SP, Saraswat N, Singh V (2026) Gene therapy targeting synaptopathy linked with Alzheimer\u2019s and Parkinson\u2019s disease. Neuroscience 600:227\u2013242. https:\/\/doi.org\/10.1016\/j.neuroscience.2026.02.035","journal-title":"Neuroscience"},{"key":"1998_CR56","doi-asserted-by":"publisher","first-page":"e70964","DOI":"10.1002\/cns.70964","volume":"32","author":"Y Peng","year":"2026","unstructured":"Peng Y, Kang XH, Yao SY, Zhang X, Kazuo S, Liu J et al (2026) Progress of immunotherapies in Parkinson\u2019s disease. CNS Neurosci Ther 32:e70964. https:\/\/doi.org\/10.1002\/cns.70964","journal-title":"CNS Neurosci Ther"},{"key":"1998_CR57","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/brainsci15060566","volume":"15","author":"MV Pomes","year":"2025","unstructured":"Pomes MV, D\u2019Urso G, Bove I, Cavallo LM, Della Ragione L, Palmiero C et al (2025) Psychiatric outcomes of subthalamic nucleus deep brain stimulation: A systematic review of short- and long-term effects. Brain Sci 15:566. https:\/\/doi.org\/10.3390\/brainsci15060566","journal-title":"Brain Sci"},{"key":"1998_CR58","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, L\u00f6schmann PA et al (2025) Levodopa treatment: Impacts and mechanisms throughout Parkinson\u2019s disease progression. J Neural Transm 132:743\u2013779. https:\/\/doi.org\/10.1007\/s00702-025-02893-4","journal-title":"J Neural Transm"},{"key":"1998_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/clinpract15060107","volume":"15","author":"JP Rissardo","year":"2025","unstructured":"Rissardo JP, Fornari Caprara AL (2025) Alpha-synuclein seed amplification assays in Parkinson\u2019s disease: A systematic review and network meta-analysis. Clin Pract 15:107. https:\/\/doi.org\/10.3390\/clinpract15060107","journal-title":"Clin Pract"},{"key":"1998_CR60","doi-asserted-by":"publisher","first-page":"20220384","DOI":"10.1098\/rstb.2022.0384","volume":"379","author":"J Rowlands","year":"2024","unstructured":"Rowlands J, Moore DJ (2024) VPS35 and retromer dysfunction in Parkinson\u2019s disease. Philosophical Trans Royal Soc B: Biol Sci 379:20220384. https:\/\/doi.org\/10.1098\/rstb.2022.0384","journal-title":"Philosophical Trans Royal Soc B: Biol Sci"},{"key":"1998_CR61","doi-asserted-by":"publisher","first-page":"110474","DOI":"10.1016\/j.jbc.2025.110474","volume":"301","author":"T Sawai","year":"2025","unstructured":"Sawai T, Nakamura Y, Arawaka S (2025) Secretory autophagy mediates lysosomal and autophagic degradation for \u03b1-synuclein proteostasis. J Biol Chem 301:110474. https:\/\/doi.org\/10.1016\/j.jbc.2025.110474","journal-title":"J Biol Chem"},{"key":"1998_CR62","doi-asserted-by":"publisher","first-page":"e2503909123","DOI":"10.1073\/pnas.2503909123","volume":"123","author":"T Schulze","year":"2026","unstructured":"Schulze T, Sprave T, Groebe C, Krumbach JH, Behringer M, Bazzone A et al (2026) Proton-selective conductance and gating of the lysosomal cation channel TMEM175. Proc Natl Acad Sci U S A 123:e2503909123. https:\/\/doi.org\/10.1073\/pnas.2503909123","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1998_CR63","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/mds.29126","volume":"37","author":"AF Schumacher-Schuh","year":"2022","unstructured":"Schumacher-Schuh AF, Bieger A, Okunoye O, Mok KY, Lim SY, Bardien S et al (2022) Underrepresented populations in Parkinson\u2019s genetics research: current landscape and future directions. Mov Disord 37:1593\u20131604. https:\/\/doi.org\/10.1002\/mds.29126","journal-title":"Mov Disord"},{"key":"1998_CR64","doi-asserted-by":"publisher","first-page":"104023","DOI":"10.1016\/j.mcn.2025.104023","volume":"134","author":"A Sharma","year":"2025","unstructured":"Sharma A, Mannan A, Singh TG (2025) Rethinking Parkinson\u2019s: The role of proteostasis networks and autophagy in disease progression. Mol Cell Neurosci 134:104023. https:\/\/doi.org\/10.1016\/j.mcn.2025.104023","journal-title":"Mol Cell Neurosci"},{"key":"1998_CR65","doi-asserted-by":"publisher","first-page":"e70676","DOI":"10.1002\/cns.70676","volume":"31","author":"Z Shen","year":"2025","unstructured":"Shen Z, Shan X, Zhang S, Huang D, Hu H, Liang Y et al (2025) Alpinetin targets mitophagy pathways to mitigate Parkinson\u2019s disease progression. CNS Neurosci Ther 31:e70676. https:\/\/doi.org\/10.1002\/cns.70676","journal-title":"CNS Neurosci Ther"},{"key":"1998_CR66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuroscience.2025.08.060","volume":"585","author":"H Singh","year":"2025","unstructured":"Singh H, Kumari S, Taliyan R (2025) Epigenetic mechanisms linking environmental exposure to Parkinson\u2019s disease: A comprehensive review. Neuroscience 585:367\u2013380. https:\/\/doi.org\/10.1016\/j.neuroscience.2025.08.060","journal-title":"Neuroscience"},{"key":"1998_CR67","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/cells13040296","volume":"13","author":"LD Skou","year":"2024","unstructured":"Skou LD, Johansen SK, Okarmus J, Meyer M (2024) Pathogenesis of DJ-1\/PARK7-mediated Parkinson\u2019s disease. Cells 13:296. https:\/\/doi.org\/10.3390\/cells13040296","journal-title":"Cells"},{"key":"1998_CR68","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3390\/brainsci15090899","volume":"15","author":"P Sobhifar","year":"2025","unstructured":"Sobhifar P, Brown DR (2025) Interaction between \u03b1-synuclein and DJ-1 in Parkinson\u2019s disease. Brain Sci 15:899. https:\/\/doi.org\/10.3390\/brainsci15090899","journal-title":"Brain Sci"},{"key":"1998_CR69","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/jamaneurol.2025.3373","volume":"82","author":"PA Starr","year":"2025","unstructured":"Starr PA, Shivacharan RS, Goldberg E, Tr\u00f6ster AI, House PA, Giroux ML et al (2025) Five-year outcomes from deep brain stimulation of the subthalamic nucleus for Parkinson disease. JAMA Neurol 82:1181\u20131190. https:\/\/doi.org\/10.1001\/jamaneurol.2025.3373","journal-title":"JAMA Neurol"},{"key":"1998_CR70","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/brainsci12101308","volume":"12","author":"G Straccia","year":"2022","unstructured":"Straccia G, Colucci F, Eleopra R, Cilia R (2022) Precision medicine in Parkinson\u2019s disease: From genetic risk signals to personalized therapy. Brain Sci 12:1308. https:\/\/doi.org\/10.3390\/brainsci12101308","journal-title":"Brain Sci"},{"key":"1998_CR71","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.3390\/biomedicines10123241","volume":"10","author":"A Surguchov","year":"2022","unstructured":"Surguchov A, Surguchev A (2022) Synucleins: new data on misfolding, aggregation and role in diseases. Biomedicines 10:3241. https:\/\/doi.org\/10.3390\/biomedicines10123241","journal-title":"Biomedicines"},{"key":"1998_CR72","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/cells14151161","volume":"14","author":"M Tanaka","year":"2025","unstructured":"Tanaka M (2025) Parkinson\u2019s disease: Bridging gaps, building biomarkers, and reimagining clinical translation. Cells 14:1161. https:\/\/doi.org\/10.3390\/cells14151161","journal-title":"Cells"},{"key":"1998_CR73","doi-asserted-by":"publisher","first-page":"106963","DOI":"10.1016\/j.biocel.2026.106963","volume":"197\u2013198","author":"P Tang","year":"2026","unstructured":"Tang P, Jing Z, Tong Z, Peng X, Tong J, Peng Y (2026) Unraveling the role of non-coding RNAs in Parkinson\u2019s disease: Molecular mechanisms and therapeutic insights. Int J Biochem Cell Biol 197\u2013198:106963. https:\/\/doi.org\/10.1016\/j.biocel.2026.106963","journal-title":"Int J Biochem Cell Biol"},{"key":"1998_CR74","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00415-026-13683-7","volume":"273","author":"M Toffoli","year":"2026","unstructured":"Toffoli M, Menozzi E, Cullen M, Chowdhury K, Ahmed S, Freemantle N et al (2026) Protocol of ASPro-PD: A phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson\u2019s disease. J Neurol 273:151. https:\/\/doi.org\/10.1007\/s00415-026-13683-7","journal-title":"J Neurol"},{"key":"1998_CR75","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/mds.30193","volume":"40","author":"AD Van Laar","year":"2025","unstructured":"Van Laar AD, Christine CW, Phielipp N, Larson PS, Elder JB, Merola A et al (2025) Intraputaminal delivery of adeno-associated virus serotype 2-glial cell line-derived neurotrophic factor in mild or moderate Parkinson\u2019s disease. Mov Disord 40:1297\u20131306. https:\/\/doi.org\/10.1002\/mds.30193","journal-title":"Mov Disord"},{"key":"1998_CR76","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405:627\u2013636. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet"},{"key":"1998_CR77","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.4103\/NRR.NRR-D-24-00771","volume":"20","author":"LX Yi","year":"2025","unstructured":"Yi LX, Woon HR, Saw G, Zeng L, Tan EK, Zhou ZD (2025) Induced pluripotent stem cell-related approaches to generate dopaminergic neurons for Parkinson\u2019s disease. Neural Regeneration Res 20:3193\u20133206. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-00771","journal-title":"Neural Regeneration Res"},{"key":"1998_CR78","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.21037\/atm-22-5159","volume":"10","author":"ZM Ying","year":"2022","unstructured":"Ying ZM, Lv QK, Yao XY, Dong AQ, Yang YP, Cao YL et al (2022) BAG3 promotes autophagy and suppresses NLRP3 inflammasome activation in Parkinson\u2019s disease. Ann Transl Med 10:1218. https:\/\/doi.org\/10.21037\/atm-22-5159","journal-title":"Ann Transl Med"},{"key":"1998_CR79","doi-asserted-by":"publisher","first-page":"8848642","DOI":"10.1155\/2023\/8848642","volume":"2023","author":"Y Yong","year":"2023","unstructured":"Yong Y, Wu Q, Meng X, Lu R, Xia H, Pei F et al (2023) Dyrk1a phosphorylation of \u03b1-synuclein mediating apoptosis of dopaminergic neurons in Parkinson\u2019s disease. Parkinsons Dis 2023:8848642. https:\/\/doi.org\/10.1155\/2023\/8848642","journal-title":"Parkinsons Dis"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-026-01998-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:03:28Z","timestamp":1790625808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-026-01998-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1998"],"URL":"https:\/\/doi.org\/10.1007\/s11011-026-01998-3","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"14 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"228"}}